First AD

Second AD

Targeting of HER3: Insights from HERTHENA-Lung01 

Please discuss the role of HER3 in the development of resistance to EGFR targeted therapies. (

Manickavasagar, et al. Lung Cancer Mang, 2021

Describe the rationale for targeting HER3 in patients with EGFR TKI resistance.

What have data shown with treatment strategies using dual targeting of HER3 and EGFR?

Please review the rationale and study design for HERTHENA-Lung01 and discuss emerging study data and its implications on the treatment landscape. (

Johnson, et al. ESMO 2023. Abstract 1319MO

Briefly outline the study design and key endpoints. What are your perceptions around the brain mets data presented at ESMO this past year?

What are some key takeaways from safety data?

What implications may these findings have on clinical practice?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates  

Peer Exchange

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial. 